Solid Dosage Forms And Dosing Regimens Comprising (2R,3S,4S,5R)-4-[[3-(3,4-Difluoro-2-Methoxy-Phenyl)-4,5-Dimethyl-5-(Trifluoromethyl) Tetrahydrofuran-2-Carbonyl]Amino]Pyridine-2-Carboxamide
Patent No. EP4346818 (titled "Solid Dosage Forms And Dosing Regimens Comprising (2R,3S,4S,5R)-4-[[3-(3,4-Difluoro-2-Methoxy-Phenyl)-4,5-Dimethyl-5-(Trifluoromethyl) Tetrahydrofuran-2-Carbonyl]Amino]Pyridine-2-Carboxamide") was filed by Vertex Pharmaceuticals Incorporated on Jun 3, 2022. The application was issued on Dec 3, 2025.
Patent Summary
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4346818
- Application Number
- EP22741050A
- Filing Date
- Jun 3, 2022
- Status
- Granted And Under Opposition
- Oct 31, 2025
- Publication Date
- Dec 3, 2025
- External Links
- Slate, Register , Google Patents